journal
MENU ▼
Read by QxMD icon Read
search

Drugs of Today

journal
https://www.readbyqxmd.com/read/29286058/european-and-americas-committees-for-treatment-and-research-in-multiple-sclerosis-ectrims-actrims-7th-joint-triennial-congress-october-25-28-2017-paris-france
#1
N Díaz
The 7th Triennial Joint conference of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) was held in Paris, France. The meeting brought together attendees from a wide range of disciplines involved in multiple sclerosis (MS) research to explore an extensive program of teaching courses, plenary lectures, oral and poster sessions from approximately 2,000 abstracts submitted, and hot topic and young investigator presentations...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29286057/notable-licensing-deals-in-the-biopharma-industry-in-the-third-quarter-of-2017
#2
P D'Souza
During the third quarter of 2017, Cortellis Competitive Intelligence registered 949 new deals (excluding mergers and acquisitions) added as part of its ongoing coverage of pharmaceutical licensing activity compared to 1,007 in Q2 this year and 1,023 in Q3 the previous year.
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29286056/sacubitril-and-valsartan-fixed-combination-to-reduce-heart-failure-events-in-post-acute-myocardial-infarction-patients
#3
M Zaid Iskandar, C C Lang
Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of the population, and is more common in the elderly, with around 6-10% of patients over 65 suffering from the condition. Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29286055/midostaurin-for-the-treatment-of-adult-patients-with-newly-diagnosed-acute-myeloid-leukemia-that-is-flt3-mutation-positive
#4
J S Garcia, M E Percival
Midostaurin is a multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits activated fms-related tyrosine kinase 3 (FLT3) in the nanomolar range and other kinases including platelet-derived growth factor receptors α (PDGFR- α) and β (PDGFR- β), cyclin-dependent kinase, proto-oncogene tyrosine-protein kinase Src, tyrosine-protein kinase Fgr, spleen tyrosine kinase (Syk), KIT proto-oncogene receptor tyrosine kinase and the major vascular endothelial growth factor receptor (VEGFR). Activating mutations in FLT3, which is one of the more common acute myeloid leukemia (AML) mutations, particularly those that result in an FLT3-ITD (internal tandem duplication) mutation, confer poor prognosis and represent a therapeutic target...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29286054/meropenem-vaborbactam-fixed-combination-for-the-treatment-of-patients-with-complicated-urinary-tract-infections
#5
M W McCarthy, T J Walsh
On August 29, 2017, the United States Food and Drug Administration (FDA) approved meropenem/ vaborbactam fixed combination for the treatment of adults with complicated urinary tract infections (cUTI). The decision was based on substantial preclinical and clinical data, including two recent trials involving hundreds of adults with cUTI. Meropenem/ vaborbactam represents a powerful new treatment option to address antibiotic-resistant pathogens, including Klebsiella pneumoniae carbapenemase-producing bacteria...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29238763/modalities-to-enumerate-circulating-tumor-cells-in-the-bloodstream-for-cancer-prognosis-and-to-monitor-the-response-to-the-therapy
#6
G Romano
Certain malignant cells may detach from the primary tumor and enter the vascular system, forming so-called circulating tumor cells (CTCs). Clusters of malignant cells associated with other cell types can also be observed in the peripheral blood of oncological patients. Such cell clusters are termed circulating tumor microemboli (CTM). The isolation and quantification of CTCs and/or CTM from blood samples allow for an accurate prognosis of the clinical course of the disease and to monitor the response to therapy...
September 2017: Drugs of Today
https://www.readbyqxmd.com/read/29238762/etelcalcetide-injectable-calcimimetic-for-the-treatment-of-secondary-hyperparathyroidism-in-hemodialysis-dependent-patients
#7
P A Ureña Torres, J Bover, M Cohen-Solal
Chronic kidney disease is associated with mineral and bone disorders that are now considered as a syndrome. One of the major complications of this syndrome is secondary hyperparathyroidism (SHPT). SHPT increases bone turnover and the risk of fracture. SHPT is also associated with cardiovascular calcification and high mortality risk. The classical medical therapies of SHPT lack long-term efficacy and have undesirable effects on serum calcium and phosphate levels. Surgical parathyroidectomy is a radical therapeutic solution potentially exposing patients to a permanent state of hypoparathyroidism among other complications...
September 2017: Drugs of Today
https://www.readbyqxmd.com/read/29238761/dupilumab-human-monoclonal-antibody-against-il-4r%C3%AE-for-moderate-to-severe-atopic-dermatitis
#8
D M Paton
Atopic dermatitis (AD) is one of the most common skin disorders with a prevalence of about 20% in children and affecting adults in significant numbers. Moderate to severe AD significantly impairs a patient's quality of life with severe pruritus as a major issue that impairs sleep and contributes to major psychological disturbances. Detailed studies of its pathogenesis have revealed that immune mechanisms are involved including activation of T helper type 2 cells (Th2). Dupilumab is a fully human Ig4 monoclonal antibody directed against the interleukin-4 receptor subunit α (IL-4Rα) of IL-4 and IL-13 receptors...
September 2017: Drugs of Today
https://www.readbyqxmd.com/read/29238760/dinutuximab-for-the-treatment-of-pediatric-patients-with-neuroblastoma
#9
K Greenwood, J H Foster
Dinutuximab is a monoclonal antibody targeted at disialoganglioside (GD2), a tumor-associated antigen widely expressed in human neuroblastoma cells. The incorporation of dinutuximab into standard treatment regimens for patients with high-risk neuroblastoma has changed the landscape of neuroblastoma therapy. Dinutuximab has shown to be effective in prolonging survival for patients receiving standard multimodal treatment regimens and has now become standard of care during the final phase of treatment. More recently, it has also shown promising efficacy and tolerability in patients with relapsed or progressive neuroblastoma...
September 2017: Drugs of Today
https://www.readbyqxmd.com/read/29119150/notable-licensing-deals-in-the-biopharma-industry-in-the-second-quarter-of-2017
#10
P D'Souza
During the second quarter of 2017, Cortellis Competitive Intelligence added 967 new licensing deals (excluding mergers and acquisition deals) as part of its ongoing coverage of pharmaceutical licensing activity. This meant an 8% decrease on the previous quarter (1,050) and a 3% decrease from the same quarter in 2016 (993). This quarter also showed a significant decline in the number of deals worth more than USD 0.5 billion from the last quarter (7 vs. 17). This article will highlight a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers in the life sciences...
August 2017: Drugs of Today
https://www.readbyqxmd.com/read/29119149/sofosbuvir-ledipasvir-fixed-dose-combination-for-treatment-of-chronic-hepatitis-c-virus-infection-in-children
#11
S A Rizza, V Nehra, Z Temesgen
The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.
August 2017: Drugs of Today
https://www.readbyqxmd.com/read/29119148/brigatinib-for-the-treatment-of-alk-positive-advanced-non-small-cell-lung-cancer-patients
#12
A Passaro, A Prelaj, A Pochesci, G Spitaleri, G Rossi, E Del Signore, C Catania, F de Marinis
Brigatinib (AP-26113, Alunbrig) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that is highly active in non-small cell lung cancer (NSCLC) harboring ALK translocation. Brigatinib was found to be very active against different ALK resistance mutations that mediate acquired resistance biology processes, particularly G1269A ALK C1156Y, I1171S/T, V1180L and others. Different clinical trials evaluated the activity of brigatinib in crizotinib-resistant patients, confirming high activity with durable response not only in parenchymal disease, but also in intracranial disease...
August 2017: Drugs of Today
https://www.readbyqxmd.com/read/29119147/betrixaban-a-direct-oral-inhibitor-of-activated-factor-x-for-the-prophylaxis-of-venous-thromboembolism-in-patients-hospitalized-for-acute-medical-illness
#13
REVIEW
G Escolar, M Díaz-Ricart, E Arellano-Rodrigo
Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a serious clinical and public health concern. Hospitalization is a major risk factor for developing VTE. Hospital-associated events account for more than 50% of all cases of VTE. Heparins have demonstrated to be efficacious in the prevention of VTE in medically ill patients. Despite the demonstrated efficacy and safety of the available direct oral anticoagulants in the prevention and treatment of different thromboembolic conditions, their net benefit in the prevention of VTE in hospitalized medically ill patients has not been fully confirmed...
August 2017: Drugs of Today
https://www.readbyqxmd.com/read/28837185/american-diabetes-association-77th-scientific-sessions-june-9-13-2017-san-diego-california-usa
#14
REVIEW
S Lam
The 77th American Diabetes Association (ADA) Sci-entific Sessions took place in San Diego, California. The meeting brought together scientists and professionals from a wide range of disciplines in the field of diabetes and provided a platform for networking, allowing experts and researchers to share ideas and learn about the significant advances in diabetes research, treatment and care. Over the course of the 5 days, participants received exclusive access to more than 2,500 original research presentations.
July 2017: Drugs of Today
https://www.readbyqxmd.com/read/28837184/checkpoint-inhibitors-a-cutting-edge-in-oncology
#15
REVIEW
C Jago
The checkpoint inhibitor field, and indeed the whole of immuno-oncology, is fast-paced and fascinating, with huge clinical and commercial potential. The challenge in the coming years will be to define the best type and combination of immunotherapy, and the best target population to receive it. Keytruda's ground-breaking approval for a biomarker-based rather than location-based indication is a solid step in this direction, and is likely to be followed by other such approvals. As the field develops, it is to be hoped that immuno-oncology therapeutics will continue to deliver the significant improvements in patient outcome that have been seen so far...
July 2017: Drugs of Today
https://www.readbyqxmd.com/read/28837183/keratitis-in-association-with-herpes-zoster-and-varicella-vaccines
#16
A P Grillo, F W Fraunfelder
The objective of this review was to collect reports of keratitis in association with herpes zoster virus (HZV) or varicella zoster virus (VZV) vaccines. HZV vaccination is intended for at-risk adult populations and VZV vaccination is intended for all pediatric patients. We reviewed the literature and reports of keratitis in association with herpes zoster or varicella vaccine from the National Registry of Drug-Induced Ocular Side Effects and the World Health Organization. Twenty-four cases of unilateral keratitis in association with VZV vaccines were collected from the adverse reaction databases and literature...
July 2017: Drugs of Today
https://www.readbyqxmd.com/read/28837182/bezlotoxumab-for-the-treatment-of-clostridium-difficile-associated-diarrhea
#17
REVIEW
R Thakare, A Dasgupta, S Chopra
Diarrhea caused by Clostridium difficile is one of the major emerging threats to modern healthcare systems worldwide. Although C. difficile spores are present in the gut innocuously, because of repeated broad-spectrum antibiotic therapy, the spores germinate with concomitant release of exotoxin A and B, resulting in mild to severe diarrhea. Antibiotic therapy is augmented by addition of the humanized antibodies actoxumab and bezlotoxumab to prevent the action of exotoxins A and B, respectively, since they provide passive immunity...
July 2017: Drugs of Today
https://www.readbyqxmd.com/read/28837181/avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma
#18
REVIEW
L M Cordes, J L Gulley
Avelumab is a promising new therapeutic agent for patients with metastatic Merkel cell carcinoma, a rare and aggressive type of neuroendocrine tumor of the skin. Until the recent approval of avelumab (Bavencio), no therapies were approved by the U.S. Food and Drug Administration for the treatment of metastatic Merkel cell carcinoma. In a recent trial, avelumab, an anti-programmed death ligand-1 antibody, demonstrated an objective response in 28 of 88 patients (31.8% [95.9% CI, 21.9-43.1]) with advanced, chemotherapy-refractory Merkel cell carcinoma...
July 2017: Drugs of Today
https://www.readbyqxmd.com/read/28799582/american-urological-association-aua-112th-annual-meeting-may-12-16-2017-boston-massachusetts-usa
#19
L Hodgkinson
The American Urological Association (AUA) stands at the forefront of technology development and urological education for urologists and urological healthcare professionals worldwide. The 112th annual meeting brought together a wide range of researchers in the field of urology to access knowledge, up-to-date clinical guidelines and advances in research. The meeting consisted of plenary and moderated poster, podium and video sessions highlighting the latest research and advances in urological medicine. This report highlights some of the presentations on therapeutic developments for a range of urological conditions...
June 2017: Drugs of Today
https://www.readbyqxmd.com/read/28799581/notable-deals-in-the-pharmaceutical-industry-in-the-first-quarter-of-2017
#20
REVIEW
E Cruces
During the first quarter of 2017, Cortellis Competitive Intelligence had 1,073 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This meant a slight increase on the last quarter (1,022) and a similar volume on the same quarter for the previous 1 year (1,141). However, this quarter showed a significant augment in deals worth more than USD 0.5 billion on the last quarter (17 vs. 12). This article will focus on highlighting a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers...
June 2017: Drugs of Today
journal
journal
40337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"